Treatment of experimental allergic encephalomyelitis (EAE) induced by guinea pig myelin basic protein epitope 72-85 with a human MBP(87-99) analogue and effects of cyclic peptides

Bioorg Med Chem. 2000 Aug;8(8):1903-9. doi: 10.1016/s0968-0896(00)00134-6.

Abstract

Experimental autoimmune encephalomyelitis (EAE) is an inflammatory and demyelinating disease of the central nervous system and is an animal model of multiple sclerosis (MS). In the present report, a linear analogue and a series of cyclic semi-mimetic peptides were designed and synthesized based on the human myelin basic protein (MBP(87-99)) epitope (Val87-His-Phe-Phe-Lys-Asn-Ile-Val-Thr-Pro-Arg-Thr-Pro90) and on Copolymer I (a mixture of random polymers of Ala, Gln, Lys and Tyr used to treat MS). These analogues were designed looking for suppressors of EAE induced by guinea pig MBP(72-85) epitope (Gln-Lys-Ser-Gln-Arg-Ser-Gln-Asp-Glu-Asn-Pro-Val) in Lewis rats. The linear analogue [Arg91,Ala96]MBP(87-99), in which Arg substitutes Lys91 and Ala substitutes Pro96, was found to be a strong inhibitor which when administered to Lewis rats together with the encephalitogenic agonist MBP(72-85) completely prevented the induction of EAE. In contrast, three N- and C-termini amide-linked cyclic semi-mimetic peptides, [cyclo-Phe-Arg-Asn-Ile-Val-Thr-Ala-Acp (1), cyclo-Phe-Ala-Arg-Gln-Acp (2), cyclo-Tyr-Ala-Lys-Gln-Acp (3)] as well as a Lys side chain and C-terminous cyclic semi mimetic peptide cyclo(Lys, Acp)-Phe-Lys-Asn-Ile-Val-Thr-Ala-Acp (4) which contain segments of MBP(87-99) or are constituted from immunophoric residues of copolymer 1, were ineffective in inducing or inhibiting EAE in Lewis rats. However co-injection of cyclic analogues with MBP(72-85) delayed the onset of EAE indicating a modulatory effect on the EAE activity of MBP(72-85). These findings suggest that molecule length, size of cyclic moiety and backbone conformation are important elements for immunogenic activity. Moreover blockade of MBP(72-85) induced EAE by the unrelated peptide [Arg91,Ala56]MBP(87-99) could indicate that the mechanism of inhibition is not due to binding competition but rather due to the delivery of a negative signal by the antagonist which overcomes the agonist response possibly through the activation of antigen specific regulatory T cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Encephalomyelitis, Autoimmune, Experimental / drug therapy*
  • Female
  • Guinea Pigs
  • Humans
  • Models, Molecular
  • Molecular Mimicry
  • Molecular Structure
  • Myelin Basic Protein / antagonists & inhibitors
  • Myelin Basic Protein / chemistry*
  • Myelin Basic Protein / immunology*
  • Myelin Basic Protein / metabolism
  • Myelin Basic Protein / pharmacology
  • Myelin Basic Protein / therapeutic use*
  • Peptide Fragments / antagonists & inhibitors
  • Peptide Fragments / chemistry*
  • Peptide Fragments / immunology*
  • Peptide Fragments / metabolism
  • Peptide Fragments / pharmacology
  • Peptide Fragments / therapeutic use*
  • Peptides, Cyclic / chemical synthesis*
  • Peptides, Cyclic / metabolism
  • Peptides, Cyclic / pharmacology
  • Peptides, Cyclic / therapeutic use*
  • Rats
  • Rats, Inbred Lew

Substances

  • Myelin Basic Protein
  • Peptide Fragments
  • Peptides, Cyclic
  • myelin basic protein 72-85
  • myelin basic protein 87-99